Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress
PASADENA, Calif. --(BUSINESS WIRE)--Jun. 23, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented positive interim results from AROHSD1001, an ongoing Phase 1/2 clinical study of ARO-HSD, the company’s investigational RNA interference (RNAi) therapeutic being developed as a
View HTML
Toggle Summary Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout
- Arrowhead to receive $40 million upfront payment - Horizon to receive a worldwide exclusive license for an investigational short interfering RNA (siRNA) therapeutic targeting xanthine dehydrogenase (XDH) PASADENA, Calif. & DUBLIN--(BUSINESS WIRE)--Jun. 21, 2021-- Arrowhead Pharmaceuticals Inc.
View HTML
Toggle Summary Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout
- Arrowhead to receive $40 million upfront payment - Horizon to receive a worldwide exclusive license for an investigational short interfering RNA (siRNA) therapeutic targeting xanthine dehydrogenase (XDH) PASADENA, Calif. & DUBLIN--(BUSINESS WIRE)--Jun. 21, 2021-- Arrowhead Pharmaceuticals Inc.
View HTML
Toggle Summary Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia
PASADENA, Calif. --(BUSINESS WIRE)--Jun. 3, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROAPOC3-2001, a Phase 2b clinical study of ARO-APOC3, the company’s investigational RNA interference (RNAi) therapeutic being developed as a
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
PASADENA, Calif. --(BUSINESS WIRE)--Jun. 2, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Jefferies Virtual Healthcare Conference – June 1-4, 2021 June 3, 2021 , 2:30 p.m.
View HTML
Toggle Summary Arrowhead Earns $10 Million Option Exercise Fee
PASADENA, Calif. --(BUSINESS WIRE)--May 18, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that Janssen Pharmaceuticals, Inc. , (Janssen) part of the Janssen Pharmaceutical Companies of Johnson & Johnson, has delivered written notice of its intent to exercise its option right
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
PASADENA, Calif. --(BUSINESS WIRE)--May 12, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 2021 RBC Capital Markets Global Healthcare – May 18-20, 2021 May 18, 2021 , 11:30 a.m.
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Fiscal 2021 Second Quarter Results
Conference Call and Webcast Today, May 4, 2021 at 4:30 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--May 4, 2021-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal second quarter ended March 31, 2021 . The company is hosting a conference call today, May
View HTML
Toggle Summary Arrowhead Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease
PASADENA, Calif. --(BUSINESS WIRE)--Apr. 28, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced positive interim 48-week liver biopsy results from the AROAAT2002 study, an open-label Phase 2 clinical study of ARO-AAT, the company’s second generation investigational RNA
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results
PASADENA, Calif. --(BUSINESS WIRE)--Apr. 16, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 4, 2021 , at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March 31, 2021 .
View HTML